Infreas båda affärsområden visar goda resultat under första halvåret och fortsätter denna utveckling...
Redeye comments on Carasent’s deal in Norway yesterday, taking over customer agreements from Confrer...
NoHo upgraded its guidance on 22 June due to strong demand in the spring and early summer, as well a...
Redeye will not make any immediate adjustments following the lowered guidance for 2022 from Remedy.
Redeye is encouraged to see another quarter in which IRRAS continues to lay the building blocks for ...
Finally, Biovica has secured US approval (510k) for DiviTum in the core market indication.
The long-awaited FDA decision announced on 30 July Management looks to have the test available by ...
Q2 still faced operational headwinds Revisions from lower organic growth assumption Fair value range...
Redeye comments on Invisio’s announcement of an order for its Intercom system worth SEK13m which is ...
Fortsatt motvind för padeln Försäljningen minskade y/y till 47 mkr (58) och EBITDA minskade till 1,2...
Redeye comments on Sleep Cycle's Q2 report, which was more or less in line with our estimates.
Redeye revisits the agreement with Bosch, which we find compelling from several perspectives.
Q2 beat on sales and adj. EBIT FY’22 guidance kept intact We leave ’22-‘24e adj.
One add-on and an important partnership in Q2 Small rise in subscription sales, while lowering care ...
Slår samtliga estimat Försäljningen i Q2 uppgick till 32,2 mkr vilket motsvarar en tillväxt om 46% y...
BankNordik set to report a solid Q2 on 4 August Fee income under pressure but insurance looks strong...
The Q2 results were largely in line with the profit warning announced on 9 June, which stated “reven...
DT releases its Q2 result on Wednesday, 3rd of Aug.
Redeye updates its estimates following Carasent’s Q2’22 report, which was a tad weaker than anticipa...
We upgrade our 2022 revenue forecast by 5%. Net sales are supported by high component prices, but th...
